Business Wire

Lithion Recycling Enters a Partnership with IS Dongseo Company for an Exclusive License of its Lithium-ion Battery Recycling Technology in South Korea

Share

Lithion Recycling, Inc. (“Lithion”) is proud to announce it has reached an agreement with IS Dongseo Company Ltd (“ISD”), a Korea-based leading ESG company with an environmental business segment, for an exclusive business right for the use of its lithium-ion battery recycling technology on the Korean market.

This partnership is the first of a series that Lithion aims to conclude in upcoming years for the use of its cutting-edge, eco-friendly technology on world markets. It will allow ISD to offer an environmentally friendly and cost-effective recycling solution to close the loop on battery materials in Korea. IS Dongseo plans to start building its first Korean facility capable of processing about 7,500 tons of waste batteries per year (or the equivalent of approximately 20,000 electric car batteries), this year. This first phase will be followed by a second one, with the construction of a hydrometallurgy plant based on Lithion’s technology, allowing ISD to supply over 15,000 tons of battery-grade materials per year.

“We are extremely proud to announce our first strategic partnership and licensing agreement with such a strong partner as IS Dongseo, an experienced battery recycling plant operator firmly rooted in the Korean market. This exclusive agreement confirms the high potential of the technology and the business model we have been developing over the years and will enable the use of our “Spoke” and “Hub” technologies on a major market for the lithium-ion battery sector. Our licensing strategy will ensure a rapid deployment of our technology globally since we are leveraging local and regional forces rather than developing and operating all plants by ourselves. This is a very exciting milestone in our quest for providing sustainable, cost-effective and locally-adapted solutions for recycling lithium-ion batteries around the globe.”

– Benoit Couture, President and CEO of Lithion Recycling, Inc.

“Recognizing that Lithion has the best battery recycling technology and following a thorough technology diligence, we are delighted to partner with them to secure full competitiveness in the battery and battery waste recycling. Korea is home base to many important and dynamic actors in the lithium-ion battery and battery materials supply chain. As these companies are rapidly expanding in Asia, in the United States and in Europe, our partnership with Lithion opens up tremendous global growth opportunities for both of us.”

– Jeon, Hyung Joon, Battery Recycle Business Director of IS Dongseo Company Ltd

The need for lithium-ion battery recycling is growing exponentially and Lithion’s commercial plants have scalable capacities to adapt to market size. Because the volume of batteries at the end of their life is spread worldwide, Lithion is planning large-scale international deployment, which will be achieved by granting licenses to strategic operating partners. The goal is to commission over 25 battery recycling plants based on Lithion’s technology in the next 15 years in cities and jurisdictions where the need is most urgent.

This is the second major announcement for Lithion in two days. On January 24, the company announced it has reached financial close on a significant first tranche of a Series A financing for up to $125 million that will be invested in the construction of its first lithium-ion battery recycling plant and a state-of-the-art Technology Development Center in Quebec, Canada as well as bringing its hydrometallurgy technology plant to breaking ground.

About Lithion Recycling, Inc.

Lithion has developed an efficient and cost-effective process to recover strategic materials from end-of-life and product waste of lithium-ion batteries. Lithion’s process allows up to 95% of battery components to be recovered and treated so that they can be reused by battery manufacturers, enabling to close the lifecycle in batteries. This technology accelerates the transition to green energy and helps meet decarbonization targets by reducing pressure on natural resource extraction. This year, Lithion launches its first commercial recycling operations, drawing on data from a highly successful Quebec industrial-scale demonstration plant commissioned in January 2020. Its goal is worldwide deployment, through licensing agreements, with a target of 20 recycling plants on a world scale. For more information, please visit: https://www.lithionrecycling.com/

About IS Dongseo Company Ltd

Established in 1975, IS Dongseo has been a leading construction group in South Korea. Over 1,000 employees and executives in the construction and manufacturing divisions are maximizing the synergy by the deployment of cutting-edge technology and the cooperative initiatives in each field. IS Dongseo is expanding in the global market by diversifying its business through entry into environment business, maritime transport and other sectors. Aligned with industry leading affiliates like Insun and KR energy and others, IS Dongseo is expanding its business territory into recycling business dealing with ESG issues. For more information, please visit: http://isdongseo.co.kr/en/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Dominik Boudreault Lapierre, dlapierre@casacom.ca, 514 386-7557

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release

Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination

Ipsen: ASCO 2022: New Cabometyx ® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer26.5.2022 23:00:00 CEST | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® (cabozantinib), across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2022) to be held on 3-7 June. Data presentations will include findings in metastatic non-small cell lung cancer (NSCLC), as well as established indications of advanced renal cell carcinoma and radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). These data show that the therapeutic potential of Cabometyx as a key treatment option in a broad range of tumors is continuing to be realized. Updated outcomes from the multicenter Phase Ib COSMIC-021 trial evaluating the combination of Cabometyx plus atezolizumab in an expanded patient population in metastatic NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune checkpoint inhib

New Better Dispensing Videos from Nordson EFD Explain Jetting Technology and How to Choose the Right Solution26.5.2022 19:00:00 CEST | Press release

Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces a new Better Dispensing™ How-To Video series. These three highly educational videos presented by EFD application specialist, Tom Muccino, provide best practices for choosing between contact dispensing and non-contact (jet) dispensing, and how to select the best jetting valve for a manufacturing application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510006079/en/ xQR41 Series MicroDot™ needle valve (left) and PICO Pµlse XP jet valve (right). (Photo: Business Wire) “One of the main differences is that with jetting, your valve never touches the surface of the part. Instead, your fluid “flies” or “jets” out of the valve, which is above the part,” Muccino explains in the first video. “This makes jetting perfect for fragile or complex parts.” Nordson EFD provides a wide range of contact and non-contact (jet

Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA26.5.2022 18:17:00 CEST | Press release

On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio). “Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca. “After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, chan

Merck to Present Latest Research From Oncology Portfolio at ASCO 202226.5.2022 18:00:00 CEST | Press release

Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies. Abstracts to be shared at the meeting include data for the Company’s licensed medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab), and its oncology pipeline. The presentations span key tumor types including advanced urothelial carcinoma (UC), advanced renal cell carcinoma (RCC), metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and head and neck cancer (SCCHN). “We look forward to coming together with the scientific community at ASCO 2022, where we will share the latest data from our portfolio, which demonstrate our determination to make a real difference in the lives of